PSA Velocity Does Not Enhance Prognostic Value of PCa Screening

KR Loughlin

ProstataABSTRACT

BACKGROUND
The value of prostate-specific antigen (PSA) for screening and management of prostate cancer (CaP) continues to engender much controversy in the medical and lay literature. This review is intended to critically analyze the literature to assess the utility of adding the calculation of PSA velocity (PSAV) in the screening and management of CaP.

METHODS
A systematic review of electronic databases including Medline PaperChase, PubMed, and Scopus was conducted to identify English-language studies in the peer-reviewed literature from 1992 to 2013. The free text search was extended by adding the following keywords: prostate cancer, screening, surgery, radiation therapy, active surveillance, and PSAV. All matches from the searches were read, and the articles pertinent to an analysis of PSAV in clinical practice were included in this review.

RESULTS
The design of much of the recent published literature on PSAV does not conform to the original description of PSAV or to the published guidelines regarding the number of PSA values and the interval of time over which the PSA values are obtained. This heterogeneity of definition is the source of much of the controversy regarding the clinical applications of PSAV. The preponderance of evidence suggests that there is high collinearity between PSA and PSAV and therefore the calculation of PSAV adds little to the measurement of PSA level.

CONCLUSIONS
PSAV calculation has been advocated by many investigators as a strategy to improve the screening and clinical management of patients with CaP. However, when PSAV definitions are rigorously applied, its calculation does not significantly enhance the clinical performance of PSA alone.

KR Loughlin
PSA Velocity: A Systematic Review of Clinical Applications
Urol. Oncol 2014 Jun 25;[EPub Ahead of Print]

The publisher has made this article available for free until 8/13/2014 12:00:00 AM .
Access this article now